Larimar Therapeutics (NASDAQ:LRMR) Stock: Insider Michael Celano Purchases 18,460 Shares

Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report) CFO Michael Celano bought 18,460 shares of the business’s stock in a transaction on Wednesday, November 11th. The stock was purchased at an average price of $2.71 per share, with a total value of $50,026.60. Following the completion of the transaction, the chief financial officer directly owned 234,245 shares of the company’s stock, valued at $634,803.95. This trade represents a 8.55% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Larimar Therapeutics Stock Up 11.9%

NASDAQ LRMR traded up $0.32 on Friday, reaching $3.02. 2,531,459 shares of the stock traded hands, compared to its average volume of 1,257,255. Larimar Therapeutics, Inc. has a 12 month low of $1.91 and a 12 month high of $6.42. The company has a market cap of $313.72 million, a price-to-earnings ratio of -1.55 and a beta of 0.73. The firm’s fifty day simple moving average is $2.93 and its 200 day simple moving average is $3.76.

Trending Headlines about Larimar Therapeutics

Investors following LRMR have been watching these headlines:

  • Positive Sentiment: CEO Carole Ben-Maimon, CFO Michael Celano, COO John B. Jr. Harlow, insider Gopi Shankar, and directors Frank Thomas and Joseph Truitt together purchased 52,810 shares for roughly $195,000. Director Thomas Hamilton separately bought 70,000 shares for $186,900. Insider purchase report Hamilton SEC filing
  • Neutral Sentiment: The supplied coverage also notes H.C. Wainwright maintained a Buy rating; no rating change or fresh price-moving catalyst was reported. Analyst rating report

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of LRMR. Blue Owl Capital Holdings LP grew its holdings in shares of Larimar Therapeutics by 0.3% in the 3rd quarter. Blue Owl Capital Holdings LP now owns 9,923,904 shares of the company’s stock worth $31,707,000 after acquiring an additional 32,147 shares during the last quarter. BlackRock Inc. acquired a new stake in shares of Larimar Therapeutics during the second quarter worth $17,318,000. Marshall Wace LLP raised its position in shares of Larimar Therapeutics by 9.1% during the third quarter. Marshall Wace LLP now owns 2,195,954 shares of the company’s stock worth $7,005,000 after purchasing an additional 183,496 shares during the period. AIGH Capital Management LLC purchased a new stake in shares of Larimar Therapeutics during the third quarter valued at $5,911,000. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Larimar Therapeutics by 143.8% during the first quarter. Dimensional Fund Advisors LP now owns 798,462 shares of the company’s stock valued at $3,592,000 after purchasing an additional 470,968 shares during the last quarter. Institutional investors own 91.92% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Wall Street Zen lowered Larimar Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday. Wedbush reissued an “outperform” rating on shares of Larimar Therapeutics in a report on Tuesday, November 10th. Leerink Partners assumed coverage on shares of Larimar Therapeutics in a research report on Monday, September 14th. They set an “outperform” rating and a $13.00 price objective for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Larimar Therapeutics in a research report on Thursday, October 15th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Larimar Therapeutics presently has a consensus rating of “Buy” and an average target price of $10.33.

Get Our Latest Stock Report on LRMR

About Larimar Therapeutics

(Get Free Report)

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases. Its lead drug candidate is nomlabofusp, formerly known as CTI-1601, an engineered fusion protein designed to deliver frataxin to mitochondria. Nomlabofusp is being developed to treat Friedreich’s ataxia, a rare, inherited neurodegenerative disorder associated with insufficient frataxin. Larimar’s approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, with the goal of addressing an underlying cause of the disease rather than only treating its symptoms.

Recommended Stories

Insider Buying and Selling by Quarter for Larimar Therapeutics (NASDAQ:LRMR)

Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.